PDS Biotechnology Corporation PDSB
0.87 USD -0.11 (-10.96%)
Regular-session close
0.86 -0.01 -1.65%
After hours · Nov 13, 7:44 PM ET
0.75 Day range 0.99
0.201 52-week range 1.60
- YTD
- +13.32%
- 1 year
- +3.27%
News
benzinga.com PDS Biotechnology Q3 EPS $(0.11) Misses $(0.09) Estimate PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 42.11 percent increase over losses of…
globenewswire.com PDS Biotech Reports Third Quarter 2026 Financial Results PRINCETON, N.J., Nov. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company focused on transforming how…
globenewswire.com PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds PRINCETON, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted…
benzinga.com B. Riley Securities Reiterates Buy on PDS Biotechnology, Raises Price Target to $4 B. Riley Securities analyst Mayank Mamtani reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $3 to $4.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pomdoctor (NASDAQ:POM) stock moved upwards by 115.1% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.9 million. Stablecoin Development…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Quantum-Si (NASDAQ:QSI) stock rose 30.3% to $1.59 during Friday's regular session. The company's market cap stands at $267.0 million. Nautilus Biotechnology (NASDAQ:NAUT) stock rose 26.09% to…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares moved upwards by 52.5% to $7.0 during Tuesday's regular session. The company's market cap stands at $6.9 million. Option Care Health (NASDAQ:OPCH)…
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million. PDS Biotechnology…
- benzinga.com PDS Biotechnology Announces Publication Of Results From Phase 2 Trial Evaluating PDS0101, HPV16-Targeted Immunotherapy, In Combination With Pembrolizumab In JAMA Oncology, Peer Reviewed Journal Of American Medical Association 39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patientsCompany continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 354.9% to $7.37 during Wednesday's regular session. The company's market cap stands at $4.9 million. Q/C Technologies (NASDAQ:QCLS) shares…
benzinga.com PDS Biotech Stock Surges Tuesday: What's Driving the Action? Shares of PDS Biotechnology Corp (NASDAQ: PDSB) are trading sharply higher Tuesday afternoon, extending Monday's gains as investors continue to react to the closing of a multi-tranche financing…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday's pre-market session. The company's market cap stands at $1.1 million. As per the press release, H1…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers AEON Biopharma (AMEX:AEON) stock moved upwards by 8.9% to $0.32 during Thursday's after-market session. The company's market cap stands at $11.5 million. Picard Medical (AMEX:PMI) stock moved…
- benzinga.com HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $5 HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $7 to $5.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology…
benzinga.com Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
benzinga.com Dow Tumbles 450 Points; US Small Business Sentiment Declines In August U.S. stocks fell Tuesday, led by a 450-point Dow drop; health care slid while energy rose. NFIB optimism weakened, oil and copper gained.
benzinga.com HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $7 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $7 price target.
benzinga.com PDS Biotechnology Says Lars Boesgaard To Resign As CFO, Principal Financial Officer & Principal Accounting Officer Effective Sept 12; Frank Bedu-Addo Appointed As Interim Principal Financial Officer On August 13, 2026, Lars Boesgaard submitted his resignation, effective as of September 12, 2026, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS…
benzinga.com HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $7 HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $15 to $7.
benzinga.com PDS Biotechnology Q2 EPS $(0.18) Misses $(0.13) Estimate PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 14.29 percent increase over losses of…
benzinga.com PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program PDS Biotechnology stock tanks as the company refocuses resources on its PDS0301 metastatic colorectal cancer program.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release,…
- benzinga.com PDS Biotechnology Announces Strategic Refocus To Prioritize PDS0301 In Metastatic Colorectal Cancer; Expects To Advance PDS0301 Through Randomized Phase 2B Development Program Over Next 18 To 24 Months "Dear Fellow Shareholders,Over the past several months, our Board of Directors and management team conducted a comprehensive review of our development portfolio, capital allocation priorities and…
- benzinga.com PDS Biotechnology Establishes Up To $50M At-The-Market Common Stock Offering Program Up to $50,000,000 Common StockWe have entered into the sales agreement (the "Sales Agreement") with Yorkville Securities, LLC ("Yorkville Securities") and B. Riley Securities, Inc. ("B. Riley…
- benzinga.com PDS Biotechnology Q1 2026 Earnings Call: Complete Transcript
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com PDS Biotechnology Q1 EPS $(0.13) Beats $(0.15) Estimate PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 38.1 percent increase over losses of…
- benzinga.com HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $15 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $15 price target.
benzinga.com Why Is PDS Biotechnology Stock Gaining Wednesday? PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com PDS Biotechnology Announces Publication Of Clinical And Immunological Biomarker Data From Stage 1 Of Phase 2 Trial Evaluating Its Tumor-Targeted IL-12 Immunocytokine, PDS01ADC, In March 10 Issue Of JCO Oncology Advances 78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of…
- benzinga.com PDS Biotechnology Q4 EPS $(0.14) Beats $(0.20) Estimate PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 33.33 percent increase over losses of…
- benzinga.com PDS Biotechnology Reports Early Positive Results In Cancer Study, Tweaks Late-Stage Cancer Trial To Speed Up Potential Approval PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today…
- benzinga.com Earnings Scheduled For March 30, 2026
- benzinga.com PDS Biotechnology Corp Reported FY25 EPS Loss Of $0.74/Share, Cash Balance Of $26.7M Full Year 2025 Financial ResultsNet loss for the year ended December 31, 2025, was approximately $34.5 million, or $0.74 per basic and diluted share, compared to a net loss of $37.6 million, or $1.03…
benzinga.com PDS Biotechnology Receives Nasdaq Noncompliance Notice, Gets Time Through Aug. 24 To Regain Compliance https://www.sec.gov/ix?doc=/Archives/edgar/data/1472091/000114036126007478/ef20067044_8k.htm#fact-identifier-5- benzinga.com PDS Biotechnology Adopts Amended Protocol To Its Phase 3 VERSATILE-003 Clinical Study PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com PDS Biotechnology Presents Results Of National Cancer Institute-Led Study Of Investigational Interleukin-12 Tumor Targeted Immunocytokine, PDS01ADC, At AACR Special Conference NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate CancerPRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology…
- benzinga.com PDS Biotechnology Announces U.S. Patent Office Issues Notice Of Allowance For Its PDS0101 Asset PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com PDS Biotechnology Submits Protocol Amendment To FDA For Its Phase 3 VERSATILE-003 Study PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com PDS Biotech Secures New Japan Patent Granting Broad Protection For PDS0101, Extending Global IP Coverage Into The 2040s New Patent Grants Broad Composition Claims for PDS0101Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the…
- benzinga.com B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $3 B. Riley Securities analyst Kalpit Patel maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $5 to $3.
- benzinga.com HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Raises Price Target to $15 HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $13 to $15.